Welcome to our dedicated page for Marchex SEC filings (Ticker: MCHX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Marchex, Inc. (NASDAQ: MCHX) SEC filings, offering a detailed view of the company’s regulatory disclosures as a Delaware corporation in the software publishers industry. Through documents such as Forms 8-K, proxy statements (DEF 14A), and other Exchange Act reports, investors can review information on governance, compensation, capital structure, and material agreements.
Recent 8-K filings describe topics including executive leadership changes, compensation arrangements, stock option and restricted stock unit grants under the company’s stock incentive plan, and the Agreement in Principle to acquire Archenia, Inc. Other filings outline how Marchex uses non-GAAP measures such as adjusted EBITDA and adjusted non-GAAP income (loss) per share, together with reconciliations to GAAP metrics. The company’s proxy statement details matters for stockholder votes, such as the election of directors and ratification of the independent registered public accounting firm, and explains its dual-class common stock voting structure.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that highlight key points, helping readers quickly understand the significance of lengthy documents. Users can review annual and quarterly reports for narrative discussion and financial disclosures, 8-Ks for material events, and proxy materials for governance and compensation information.
For those tracking insider and equity-related activity, filings related to stock incentive plans and director or executive compensation provide insight into option grants, RSUs, and change-in-control terms. By combining real-time access to Marchex’s official filings with AI-generated explanations, this page helps investors and analysts interpret how corporate actions, governance decisions, and strategic initiatives are reflected in the company’s regulatory record.
Marchex, Inc. updated executive compensation and approved new equity awards. The Compensation Committee set annual base salaries at $400,000 for Troy Hartless (President & Chief Revenue Officer), $375,000 for Francis Feeney (Chief Operating Officer & Chief Legal Officer), and $275,000 for Brian Nagle (Chief Financial Officer), effective on the October 16, 2025 grant date.
The committee granted stock options of 150,000 to each of Hartless and Feeney and 125,000 to Nagle under the 2021 Stock Incentive Plan. Options vest over four years: 25% on the first anniversary of the grant date, then quarterly in equal 6.25% increments over the next three years, with an exercise price equal to the closing price on the grant date. It also granted RSUs of 150,000 to Hartless and Feeney and 125,000 to Nagle, each vesting in full on the fourth anniversary.
For Nagle, the company aligned employment terms with other executives. Upon certain terminations following a change in control, he is eligible for a lump sum equal to 12 months of base salary, prior-year earned bonus (capped at 100% of salary), and 12 months of COBRA. Death or disability provides 18 months of COBRA, and specified events trigger full vesting of unvested equity.
Marchex (MCHX) reported insider equity awards for its Chief Financial Officer dated 10/16/2025. The filing shows 125,000 restricted stock units tied to Class B Common Stock, which vest in full on the fourth anniversary of the grant date. It also lists 125,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest 25% on the first anniversary, then quarterly over the following three years in equal 6.25% increments.
Marchex (MCHX) reported an insider equity grant to its Chief Operating Officer & CLO. On 10/16/2025, the executive received 150,000 restricted stock units, each settling into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date.
On the same date, the executive was also granted 150,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest over four years: 25% on the first anniversary, then quarterly in equal 6.25% increments over the next three years.
Marchex (MCHX) filed a Form 4 reporting equity awards to its President & Chief Revenue Officer effective October 16, 2025. The filing discloses 150,000 restricted stock units, each convertible into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date. It also reports stock options for 150,000 shares at an exercise price of $1.81 per share, expiring October 16, 2035, vesting 25% on the first anniversary and the remainder in equal quarterly installments over the next three years.
Francis J. Feeney, Chief Operating Officer of Marchex, Inc. (MCHX), filed a Form 3 disclosing his initial beneficial ownership. The filing reports 277,428 shares of Class B common stock held directly and a portfolio of equity awards that could convert to additional shares.
The derivative holdings include employee stock options to purchase 848,000 shares with exercise prices ranging from $1.45 to $5.05 and expiration dates between 2028 and 2034, plus 62,500 restricted stock units that vest in full on the first anniversary of their March 20, 2025 grant. All reported holdings are direct and subject to specified vesting schedules tied to continued employment.
Marchex, Inc. reported a major leadership transition. Edwin A. Miller resigned as Chief Executive Officer effective September 11, 2025, and will serve for one year as a consultant to the company’s Chairman, providing general advisory services for $150,000 in annual compensation and remaining eligible for his 2025 annual cash performance bonus.
Effective September 15, 2025, Troy Hartless was appointed President while continuing as Chief Revenue Officer, and Francis J. Feeney was appointed Chief Operating Officer while continuing as Chief Legal Officer. Brian Nagle was appointed Chief Financial Officer, moving up from Senior Vice President, Controller. Hartless and Feeney will serve as Co-Principal Executive Officers for SEC reporting purposes. The company states there were no changes in compensation for Hartless, Feeney, or Nagle in connection with these appointments and discloses no related-party transactions or family relationships.
Marchex reported revenue of $11.655 million for the quarter ended June 30, 2025, down 3% from $12.074 million a year earlier, and $23.058 million for the six months, down 2% year over year. The company recorded a small quarterly net income of $85 thousand (basic and diluted EPS $0.00) after narrowing its operating loss, but posted a six-month net loss of $1.897 million (basic/diluted loss per share approximately $0.04). Cash and cash equivalents were $10.491 million, total assets $41.984 million, and accumulated deficit $328.075 million.
Operational highlights: sales and marketing expense increased while product development declined due to capitalization and reorganization; cost of revenue remained ~35% of revenue. The company recognized a ~$0.6 million gain from a domain sale, authorized a new repurchase program to buy up to 3,000,000 Class B shares (no repurchases made), and recorded a 100% valuation allowance against deferred tax assets. One customer accounted for ~11% of revenue and 21% of receivables, and litigation over a prior acquisition earnout is in discovery.
Marchex, Inc. announced it is issuing an earnings release and holding a conference call to report results for the quarter ended June 30, 2025. The full earnings release is furnished as Exhibit 99.1 to the Current Report. The company discloses it will present both GAAP and non-GAAP financial measures; the release includes reconciliations and definitions explaining why management believes the non-GAAP measures are useful to investors. The 8-K furnishes this information rather than treating it as formally "filed" under the Exchange Act.